Tuesday, June 6, 2023
Home Authors Posts by Editor / Curator

Editor / Curator

755 POSTS 0 COMMENTS
2022 Watch List

Maxim Group Targets 175% Gain in Society Pass (SOPA) to $2.75.

Editor / Curator -
Alternative Energy

Updating Coverage Report: Two Binary Events Rapidly Approaching Principal Solar (PSWW).

Editor / Curator -
Featured

Hidden Gem and a Monster in the Making? Beasley Broadcast Group...

Editor / Curator -
2023 Watch List

Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for...

Editor / Curator -
Incubator

Smart for Life (SMFL) Reports Revenue Increases 96.9% to $17.8 Million...

Editor / Curator -
Marijuana Stock Review

Adding Vext Science (VEXTF) $0.17 to the Watch List.

Editor / Curator -
Incubator

Report: Think Equity Updates Society Pass (SOPA). $6.00 Price Target.

Editor / Curator -
Alternative Energy

IA Initiates Analyst Coverage of Principal Solar (Press Release).

Editor / Curator -
All News

Selling ARK (ARKK) & Buying AXS Short Innovation (SARK) ETF.

Editor / Curator -
2022 Watch List

We’re Bearish, but we’re up 257% in Provention Bio (PRVB) Today.

Editor / Curator -
1234...76Page 3 of 76

Latest article

Asia-Pacific: A Region of Stability Amidst Economic Uncertainty

2022 Watch List Editor / Curator -
Contrary to the Western markets, there is a growing consensus that the Asia Pacific is emerging as a relatively safe harbour in...

Hepion (HEPA) Back in the Spotlight, Gains 230% in May.

2020 Watch List Editor / Curator -
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...

2023 Watch List Editor / Curator -
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: roland@institutionalanalyst.com
© Managed by Revelers.IO Media Group Inc.